Roche to bid $5.7bn for DNA firm Illumina
Swiss drugmaker Roche has said it plans to make an offer of $5.7bn (£3.7bn) for DNA research company Illumina.
Roche said the deal would help it meet the growing demand for genetic solutions and speed up the use of DNA research in routine medical diagnosis.
The firm said it expected Illumina shareholders to “welcome the opportunity” to sell their shares.